Cancer Therapeutics ups stake in NanoTherapies

Cancer Therapeutics, has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, giving Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies. Release